Novavax, Inc. (NVAX)


+0.58 (+8.18%)
Symbol NVAX
Price $7.67
Beta 1.683
Volume Avg. 9.18M
Market Cap 773.934M
Shares () -
52 Week Range 5.61-25.66
1y Target Est -
DCF Unlevered NVAX DCF ->
DCF Levered NVAX LDCF ->
ROE 82.35% Strong Buy
ROA -34.82% Strong Sell
Operating Margin -
Debt / Equity -26.37% Neutral
P/E -1.08 Sell
P/B -0.91


Consensus EPS

Upgrades & Downgrades

Latest NVAX news

Mr. John Charles Jacobs M.B.A.
NASDAQ Global Select

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.